Senior advisor to NextGen Invent Corporation
Large language models and natural language processing are reshaping drug safety surveillance by enabling automated adverse event detection, large-scale analysis of regulatory labeling data, and faster, citation-grounded safety assessments while maintaining human oversight and regulatory compliance.
As the AI-first era matures, life sciences leaders must pivot from narrow, task-specific models toward integrated, interpretable frameworks that transform biological complexity into a sustainable competitive advantage.
Can deeper data from specialty pharmacy providers bolster both patient outcomes and financial returns?
Strategies and recommendations for driving value in today’s AI-enhanced prescribing environment.
The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions.
A patient-centric approach to drug development delivers the benefits that actually create value.
Pharmaceutical Executive
Innovation in hub program design for patient scrip data and clinical support services can lead to increased market share in the hotly contested specialty medicine space.
